Risk factors of NSAID-exacerbated respiratory disease: A population-based study.

"CONFLICT OF INTEREST STATEMENT ST‐S reports consultancies for ALK‐Abelló, AstraZeneca, ERT, GSK, Novartis, Sanofi, and Roche Products outside the submitted work as well as grant of GSK outside the submitted work. JB reports personal fees from Cipla, Menarini, Mylan, Novartis, Purina, Sanofi‐Aventis, Teva, Uriach, other from KYomed‐Innov, other from Mask‐air‐SAS, outside the submitted work. JK reports personal fees from GlaxoSmithKline, MSD, Novartis, Sanofi, AstraZeneca, Boehringer Ingelheim, Chiesi, and Orion Pharma, outside the submitted work. AL reports personal fees from GlaxoSmithKline and CSL Behring outside the submitted work. All other authors declare no conflicts of interest."

"We express our gratitude to the following people for their valuable contributions to this study: Professor Arpo Aromaa from the National Institute for Health and Welfare and Professor Markku M. Nieminen from the University of Tampere, and Professor Timo Klaukka† from the University of Helsinki. The study was partly supported by research grants from State funding for University‐Level Health Research (TYH2019322), the Finnish Anti‐Tuberculosis Foundation, the Tampere Tuberculosis Foundation, the Väinö and Laina Kivi Foundation, the Sohlberg Foundation, the MD PhD Programme of the Faculty of Medicine in University of Helsinki, and the European Academy of Allergy and Clinical Immunology (travel grant)."